Baidu
map

JAMA:正接受ART治疗且习惯无套性行为的HIV患者可能并不会出现HIV伴侣内传播

2016-07-13 MedSci MedSci原创

抗逆转录病毒治疗(ART)作为一种预防策略,在评估其有效性和成本效益时的一个关键因素是无套性行为时HIV传播的绝对风险。本研究旨在评估无套性行为期间情侣之间HIV的传播率(异性恋、男男性行为[MSM]),以及HIV阳性的伴侣HIV-1 RNA载量低于200拷贝/毫升时的HIV的传播率。在欧洲14个国家的75个临床基地进行此前瞻性观察性PARTNER研究,共纳入1166名无套性行为(2010年9月至

抗逆转录病毒治疗(ART)作为一种预防策略,在评估其有效性和成本效益时的一个关键因素是无套性行为时HIV传播的绝对风险。本研究旨在评估无套性行为期间情侣之间HIV的传播率(异性恋、男男性行为[MSM]),以及HIV阳性的伴侣HIV-1 RNA载量低于200拷贝/毫升时的HIV的传播率。

在欧洲14个国家的75个临床基地进行此前瞻性观察性PARTNER研究,共纳入1166名无套性行为(2010年9月至2014年5月)参与者。随访期间的纳入标准为HIV-1 RNA载量小于200拷贝/毫升。使用匿名系统分析对比了夫妻的HIV-1聚合酶和衣壳序列,如果HIV阴性的伴侣感染HIV则可确定发生了系统相关的病毒传播。

暴露条件为无套性行为,且HIV阳性的伴侣接受ART治疗。主要研究结果为HIV阳性伴侣将HIV传播至HIV阴性伴侣的风险。

纳入的1166名伴侣中,888名(平均年龄为42岁;548名 [ 61.7% ]为异性恋,340名 [ 38.3% ]为MSM)伴侣提供了1238合格的伴侣随访时间(中位随访时间为1.3年)。基线时期,伴侣无套性行为的时间为2年(中位数)。108 名(33%)HIV阴性的MSM参与者和21名(4%)异性恋者与其他人发生过无套性行为。随访期间,伴侣无套性行为的次数为每年37次(中位数),MSM伴侣共发生了约22000次,异性恋者共发生了约约36000次。虽然11名HIV阴性的伴侣感染了HIV,但是在随访期间并无与传播系统相关的系统发生,伴侣内HIV的传播率为零,伴侣随访期间 95%的置信区间的上限为0.30/100。无套肛交伴侣随访期间的95%可信区间上限为是0.71/100。

总而言之,HIV阳性者使用抑制ART治疗且习惯无套性行为的异性恋伴侣及MSM伴侣中,在平均随访的1.3年中(每位伴侣),并没有关于伴侣内HIV传播的记录。仍需额外的长期随访以提供更精确的风险估计。

原始估计:

Alison J. Rodger,  Valentina Cambiano, et al., Sexual Activity Without Condoms and Risk of HIV Transmission in Serodifferent Couples When the HIV-Positive Partner Is Using Suppressive Antiretroviral Therapy. JAMA. 2016;316(2):171-181. doi:10.1001/jama.2016.5148.


版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (8)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=141757, encodeId=896f141e571c, content=文章很棒,继续学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=116, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzdAIB7UwTkHt6fQkBP8ictliaXtc5gCUmYdAW1sAETC2nhO3q6YjRHkUibyOCtP8ibmXNObTyd63A076/0, createdBy=d4111948983, createdName=1e10c84am36(暂无匿称), createdTime=Sat Oct 08 08:37:38 CST 2016, time=2016-10-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2003347, encodeId=d657200334ebe, content=<a href='/topic/show?id=5012890397' target=_blank style='color:#2F92EE;'>#HIV患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=100, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8903, encryptionId=5012890397, topicName=HIV患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b505306, createdName=医生2394, createdTime=Wed Jun 14 09:39:00 CST 2017, time=2017-06-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1322359, encodeId=ca4d1322359f4, content=<a href='/topic/show?id=cde152e227a' target=_blank style='color:#2F92EE;'>#性行为#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=91, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=52722, encryptionId=cde152e227a, topicName=性行为)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1e1c493, createdName=xugc, createdTime=Fri Jul 15 11:39:00 CST 2016, time=2016-07-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1356088, encodeId=1c501356088ea, content=<a href='/topic/show?id=b0702e84b9' target=_blank style='color:#2F92EE;'>#ART#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=103, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2784, encryptionId=b0702e84b9, topicName=ART)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Fri Jul 15 11:39:00 CST 2016, time=2016-07-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1479615, encodeId=3c9914e96158e, content=<a href='/topic/show?id=762b2e9464' target=_blank style='color:#2F92EE;'>#ART治疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=81, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2794, encryptionId=762b2e9464, topicName=ART治疗)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ec107553788, createdName=ms55066533437992, createdTime=Fri Jul 15 11:39:00 CST 2016, time=2016-07-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1615842, encodeId=ac59161584286, content=<a href='/topic/show?id=5882260898d' target=_blank style='color:#2F92EE;'>#伴侣#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=26089, encryptionId=5882260898d, topicName=伴侣)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2b3b19689320, createdName=ms3892185887221420, createdTime=Fri Jul 15 11:39:00 CST 2016, time=2016-07-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=93112, encodeId=a62d9311221, content=要注意防护措施, beContent=null, objectType=article, channel=null, level=null, likeNumber=142, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=90f31612316, createdName=xiaotaiyang1, createdTime=Thu Jul 14 19:19:00 CST 2016, time=2016-07-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=93030, encodeId=179293030e0, content=算是研究的进步,不过存在HIV感染率升高的风险, beContent=null, objectType=article, channel=null, level=null, likeNumber=130, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20170701/IMG595791009FB761316.jpg, createdBy=abd01695121, createdName=吴教授, createdTime=Thu Jul 14 08:12:00 CST 2016, time=2016-07-14, status=1, ipAttribution=)]
    2016-10-08 1e10c84am36(暂无匿称)

    文章很棒,继续学习

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=141757, encodeId=896f141e571c, content=文章很棒,继续学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=116, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzdAIB7UwTkHt6fQkBP8ictliaXtc5gCUmYdAW1sAETC2nhO3q6YjRHkUibyOCtP8ibmXNObTyd63A076/0, createdBy=d4111948983, createdName=1e10c84am36(暂无匿称), createdTime=Sat Oct 08 08:37:38 CST 2016, time=2016-10-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2003347, encodeId=d657200334ebe, content=<a href='/topic/show?id=5012890397' target=_blank style='color:#2F92EE;'>#HIV患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=100, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8903, encryptionId=5012890397, topicName=HIV患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b505306, createdName=医生2394, createdTime=Wed Jun 14 09:39:00 CST 2017, time=2017-06-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1322359, encodeId=ca4d1322359f4, content=<a href='/topic/show?id=cde152e227a' target=_blank style='color:#2F92EE;'>#性行为#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=91, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=52722, encryptionId=cde152e227a, topicName=性行为)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1e1c493, createdName=xugc, createdTime=Fri Jul 15 11:39:00 CST 2016, time=2016-07-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1356088, encodeId=1c501356088ea, content=<a href='/topic/show?id=b0702e84b9' target=_blank style='color:#2F92EE;'>#ART#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=103, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2784, encryptionId=b0702e84b9, topicName=ART)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Fri Jul 15 11:39:00 CST 2016, time=2016-07-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1479615, encodeId=3c9914e96158e, content=<a href='/topic/show?id=762b2e9464' target=_blank style='color:#2F92EE;'>#ART治疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=81, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2794, encryptionId=762b2e9464, topicName=ART治疗)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ec107553788, createdName=ms55066533437992, createdTime=Fri Jul 15 11:39:00 CST 2016, time=2016-07-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1615842, encodeId=ac59161584286, content=<a href='/topic/show?id=5882260898d' target=_blank style='color:#2F92EE;'>#伴侣#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=26089, encryptionId=5882260898d, topicName=伴侣)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2b3b19689320, createdName=ms3892185887221420, createdTime=Fri Jul 15 11:39:00 CST 2016, time=2016-07-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=93112, encodeId=a62d9311221, content=要注意防护措施, beContent=null, objectType=article, channel=null, level=null, likeNumber=142, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=90f31612316, createdName=xiaotaiyang1, createdTime=Thu Jul 14 19:19:00 CST 2016, time=2016-07-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=93030, encodeId=179293030e0, content=算是研究的进步,不过存在HIV感染率升高的风险, beContent=null, objectType=article, channel=null, level=null, likeNumber=130, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20170701/IMG595791009FB761316.jpg, createdBy=abd01695121, createdName=吴教授, createdTime=Thu Jul 14 08:12:00 CST 2016, time=2016-07-14, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=141757, encodeId=896f141e571c, content=文章很棒,继续学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=116, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzdAIB7UwTkHt6fQkBP8ictliaXtc5gCUmYdAW1sAETC2nhO3q6YjRHkUibyOCtP8ibmXNObTyd63A076/0, createdBy=d4111948983, createdName=1e10c84am36(暂无匿称), createdTime=Sat Oct 08 08:37:38 CST 2016, time=2016-10-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2003347, encodeId=d657200334ebe, content=<a href='/topic/show?id=5012890397' target=_blank style='color:#2F92EE;'>#HIV患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=100, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8903, encryptionId=5012890397, topicName=HIV患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b505306, createdName=医生2394, createdTime=Wed Jun 14 09:39:00 CST 2017, time=2017-06-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1322359, encodeId=ca4d1322359f4, content=<a href='/topic/show?id=cde152e227a' target=_blank style='color:#2F92EE;'>#性行为#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=91, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=52722, encryptionId=cde152e227a, topicName=性行为)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1e1c493, createdName=xugc, createdTime=Fri Jul 15 11:39:00 CST 2016, time=2016-07-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1356088, encodeId=1c501356088ea, content=<a href='/topic/show?id=b0702e84b9' target=_blank style='color:#2F92EE;'>#ART#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=103, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2784, encryptionId=b0702e84b9, topicName=ART)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Fri Jul 15 11:39:00 CST 2016, time=2016-07-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1479615, encodeId=3c9914e96158e, content=<a href='/topic/show?id=762b2e9464' target=_blank style='color:#2F92EE;'>#ART治疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=81, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2794, encryptionId=762b2e9464, topicName=ART治疗)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ec107553788, createdName=ms55066533437992, createdTime=Fri Jul 15 11:39:00 CST 2016, time=2016-07-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1615842, encodeId=ac59161584286, content=<a href='/topic/show?id=5882260898d' target=_blank style='color:#2F92EE;'>#伴侣#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=26089, encryptionId=5882260898d, topicName=伴侣)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2b3b19689320, createdName=ms3892185887221420, createdTime=Fri Jul 15 11:39:00 CST 2016, time=2016-07-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=93112, encodeId=a62d9311221, content=要注意防护措施, beContent=null, objectType=article, channel=null, level=null, likeNumber=142, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=90f31612316, createdName=xiaotaiyang1, createdTime=Thu Jul 14 19:19:00 CST 2016, time=2016-07-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=93030, encodeId=179293030e0, content=算是研究的进步,不过存在HIV感染率升高的风险, beContent=null, objectType=article, channel=null, level=null, likeNumber=130, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20170701/IMG595791009FB761316.jpg, createdBy=abd01695121, createdName=吴教授, createdTime=Thu Jul 14 08:12:00 CST 2016, time=2016-07-14, status=1, ipAttribution=)]
    2016-07-15 xugc
  4. [GetPortalCommentsPageByObjectIdResponse(id=141757, encodeId=896f141e571c, content=文章很棒,继续学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=116, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzdAIB7UwTkHt6fQkBP8ictliaXtc5gCUmYdAW1sAETC2nhO3q6YjRHkUibyOCtP8ibmXNObTyd63A076/0, createdBy=d4111948983, createdName=1e10c84am36(暂无匿称), createdTime=Sat Oct 08 08:37:38 CST 2016, time=2016-10-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2003347, encodeId=d657200334ebe, content=<a href='/topic/show?id=5012890397' target=_blank style='color:#2F92EE;'>#HIV患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=100, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8903, encryptionId=5012890397, topicName=HIV患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b505306, createdName=医生2394, createdTime=Wed Jun 14 09:39:00 CST 2017, time=2017-06-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1322359, encodeId=ca4d1322359f4, content=<a href='/topic/show?id=cde152e227a' target=_blank style='color:#2F92EE;'>#性行为#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=91, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=52722, encryptionId=cde152e227a, topicName=性行为)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1e1c493, createdName=xugc, createdTime=Fri Jul 15 11:39:00 CST 2016, time=2016-07-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1356088, encodeId=1c501356088ea, content=<a href='/topic/show?id=b0702e84b9' target=_blank style='color:#2F92EE;'>#ART#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=103, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2784, encryptionId=b0702e84b9, topicName=ART)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Fri Jul 15 11:39:00 CST 2016, time=2016-07-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1479615, encodeId=3c9914e96158e, content=<a href='/topic/show?id=762b2e9464' target=_blank style='color:#2F92EE;'>#ART治疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=81, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2794, encryptionId=762b2e9464, topicName=ART治疗)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ec107553788, createdName=ms55066533437992, createdTime=Fri Jul 15 11:39:00 CST 2016, time=2016-07-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1615842, encodeId=ac59161584286, content=<a href='/topic/show?id=5882260898d' target=_blank style='color:#2F92EE;'>#伴侣#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=26089, encryptionId=5882260898d, topicName=伴侣)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2b3b19689320, createdName=ms3892185887221420, createdTime=Fri Jul 15 11:39:00 CST 2016, time=2016-07-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=93112, encodeId=a62d9311221, content=要注意防护措施, beContent=null, objectType=article, channel=null, level=null, likeNumber=142, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=90f31612316, createdName=xiaotaiyang1, createdTime=Thu Jul 14 19:19:00 CST 2016, time=2016-07-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=93030, encodeId=179293030e0, content=算是研究的进步,不过存在HIV感染率升高的风险, beContent=null, objectType=article, channel=null, level=null, likeNumber=130, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20170701/IMG595791009FB761316.jpg, createdBy=abd01695121, createdName=吴教授, createdTime=Thu Jul 14 08:12:00 CST 2016, time=2016-07-14, status=1, ipAttribution=)]
    2016-07-15 zhaojie88
  5. [GetPortalCommentsPageByObjectIdResponse(id=141757, encodeId=896f141e571c, content=文章很棒,继续学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=116, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzdAIB7UwTkHt6fQkBP8ictliaXtc5gCUmYdAW1sAETC2nhO3q6YjRHkUibyOCtP8ibmXNObTyd63A076/0, createdBy=d4111948983, createdName=1e10c84am36(暂无匿称), createdTime=Sat Oct 08 08:37:38 CST 2016, time=2016-10-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2003347, encodeId=d657200334ebe, content=<a href='/topic/show?id=5012890397' target=_blank style='color:#2F92EE;'>#HIV患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=100, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8903, encryptionId=5012890397, topicName=HIV患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b505306, createdName=医生2394, createdTime=Wed Jun 14 09:39:00 CST 2017, time=2017-06-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1322359, encodeId=ca4d1322359f4, content=<a href='/topic/show?id=cde152e227a' target=_blank style='color:#2F92EE;'>#性行为#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=91, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=52722, encryptionId=cde152e227a, topicName=性行为)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1e1c493, createdName=xugc, createdTime=Fri Jul 15 11:39:00 CST 2016, time=2016-07-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1356088, encodeId=1c501356088ea, content=<a href='/topic/show?id=b0702e84b9' target=_blank style='color:#2F92EE;'>#ART#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=103, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2784, encryptionId=b0702e84b9, topicName=ART)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Fri Jul 15 11:39:00 CST 2016, time=2016-07-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1479615, encodeId=3c9914e96158e, content=<a href='/topic/show?id=762b2e9464' target=_blank style='color:#2F92EE;'>#ART治疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=81, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2794, encryptionId=762b2e9464, topicName=ART治疗)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ec107553788, createdName=ms55066533437992, createdTime=Fri Jul 15 11:39:00 CST 2016, time=2016-07-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1615842, encodeId=ac59161584286, content=<a href='/topic/show?id=5882260898d' target=_blank style='color:#2F92EE;'>#伴侣#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=26089, encryptionId=5882260898d, topicName=伴侣)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2b3b19689320, createdName=ms3892185887221420, createdTime=Fri Jul 15 11:39:00 CST 2016, time=2016-07-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=93112, encodeId=a62d9311221, content=要注意防护措施, beContent=null, objectType=article, channel=null, level=null, likeNumber=142, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=90f31612316, createdName=xiaotaiyang1, createdTime=Thu Jul 14 19:19:00 CST 2016, time=2016-07-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=93030, encodeId=179293030e0, content=算是研究的进步,不过存在HIV感染率升高的风险, beContent=null, objectType=article, channel=null, level=null, likeNumber=130, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20170701/IMG595791009FB761316.jpg, createdBy=abd01695121, createdName=吴教授, createdTime=Thu Jul 14 08:12:00 CST 2016, time=2016-07-14, status=1, ipAttribution=)]
  6. [GetPortalCommentsPageByObjectIdResponse(id=141757, encodeId=896f141e571c, content=文章很棒,继续学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=116, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzdAIB7UwTkHt6fQkBP8ictliaXtc5gCUmYdAW1sAETC2nhO3q6YjRHkUibyOCtP8ibmXNObTyd63A076/0, createdBy=d4111948983, createdName=1e10c84am36(暂无匿称), createdTime=Sat Oct 08 08:37:38 CST 2016, time=2016-10-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2003347, encodeId=d657200334ebe, content=<a href='/topic/show?id=5012890397' target=_blank style='color:#2F92EE;'>#HIV患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=100, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8903, encryptionId=5012890397, topicName=HIV患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b505306, createdName=医生2394, createdTime=Wed Jun 14 09:39:00 CST 2017, time=2017-06-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1322359, encodeId=ca4d1322359f4, content=<a href='/topic/show?id=cde152e227a' target=_blank style='color:#2F92EE;'>#性行为#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=91, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=52722, encryptionId=cde152e227a, topicName=性行为)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1e1c493, createdName=xugc, createdTime=Fri Jul 15 11:39:00 CST 2016, time=2016-07-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1356088, encodeId=1c501356088ea, content=<a href='/topic/show?id=b0702e84b9' target=_blank style='color:#2F92EE;'>#ART#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=103, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2784, encryptionId=b0702e84b9, topicName=ART)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Fri Jul 15 11:39:00 CST 2016, time=2016-07-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1479615, encodeId=3c9914e96158e, content=<a href='/topic/show?id=762b2e9464' target=_blank style='color:#2F92EE;'>#ART治疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=81, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2794, encryptionId=762b2e9464, topicName=ART治疗)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ec107553788, createdName=ms55066533437992, createdTime=Fri Jul 15 11:39:00 CST 2016, time=2016-07-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1615842, encodeId=ac59161584286, content=<a href='/topic/show?id=5882260898d' target=_blank style='color:#2F92EE;'>#伴侣#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=26089, encryptionId=5882260898d, topicName=伴侣)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2b3b19689320, createdName=ms3892185887221420, createdTime=Fri Jul 15 11:39:00 CST 2016, time=2016-07-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=93112, encodeId=a62d9311221, content=要注意防护措施, beContent=null, objectType=article, channel=null, level=null, likeNumber=142, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=90f31612316, createdName=xiaotaiyang1, createdTime=Thu Jul 14 19:19:00 CST 2016, time=2016-07-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=93030, encodeId=179293030e0, content=算是研究的进步,不过存在HIV感染率升高的风险, beContent=null, objectType=article, channel=null, level=null, likeNumber=130, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20170701/IMG595791009FB761316.jpg, createdBy=abd01695121, createdName=吴教授, createdTime=Thu Jul 14 08:12:00 CST 2016, time=2016-07-14, status=1, ipAttribution=)]
  7. [GetPortalCommentsPageByObjectIdResponse(id=141757, encodeId=896f141e571c, content=文章很棒,继续学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=116, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzdAIB7UwTkHt6fQkBP8ictliaXtc5gCUmYdAW1sAETC2nhO3q6YjRHkUibyOCtP8ibmXNObTyd63A076/0, createdBy=d4111948983, createdName=1e10c84am36(暂无匿称), createdTime=Sat Oct 08 08:37:38 CST 2016, time=2016-10-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2003347, encodeId=d657200334ebe, content=<a href='/topic/show?id=5012890397' target=_blank style='color:#2F92EE;'>#HIV患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=100, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8903, encryptionId=5012890397, topicName=HIV患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b505306, createdName=医生2394, createdTime=Wed Jun 14 09:39:00 CST 2017, time=2017-06-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1322359, encodeId=ca4d1322359f4, content=<a href='/topic/show?id=cde152e227a' target=_blank style='color:#2F92EE;'>#性行为#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=91, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=52722, encryptionId=cde152e227a, topicName=性行为)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1e1c493, createdName=xugc, createdTime=Fri Jul 15 11:39:00 CST 2016, time=2016-07-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1356088, encodeId=1c501356088ea, content=<a href='/topic/show?id=b0702e84b9' target=_blank style='color:#2F92EE;'>#ART#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=103, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2784, encryptionId=b0702e84b9, topicName=ART)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Fri Jul 15 11:39:00 CST 2016, time=2016-07-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1479615, encodeId=3c9914e96158e, content=<a href='/topic/show?id=762b2e9464' target=_blank style='color:#2F92EE;'>#ART治疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=81, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2794, encryptionId=762b2e9464, topicName=ART治疗)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ec107553788, createdName=ms55066533437992, createdTime=Fri Jul 15 11:39:00 CST 2016, time=2016-07-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1615842, encodeId=ac59161584286, content=<a href='/topic/show?id=5882260898d' target=_blank style='color:#2F92EE;'>#伴侣#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=26089, encryptionId=5882260898d, topicName=伴侣)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2b3b19689320, createdName=ms3892185887221420, createdTime=Fri Jul 15 11:39:00 CST 2016, time=2016-07-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=93112, encodeId=a62d9311221, content=要注意防护措施, beContent=null, objectType=article, channel=null, level=null, likeNumber=142, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=90f31612316, createdName=xiaotaiyang1, createdTime=Thu Jul 14 19:19:00 CST 2016, time=2016-07-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=93030, encodeId=179293030e0, content=算是研究的进步,不过存在HIV感染率升高的风险, beContent=null, objectType=article, channel=null, level=null, likeNumber=130, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20170701/IMG595791009FB761316.jpg, createdBy=abd01695121, createdName=吴教授, createdTime=Thu Jul 14 08:12:00 CST 2016, time=2016-07-14, status=1, ipAttribution=)]
    2016-07-14 xiaotaiyang1

    要注意防护措施

    0

  8. [GetPortalCommentsPageByObjectIdResponse(id=141757, encodeId=896f141e571c, content=文章很棒,继续学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=116, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzdAIB7UwTkHt6fQkBP8ictliaXtc5gCUmYdAW1sAETC2nhO3q6YjRHkUibyOCtP8ibmXNObTyd63A076/0, createdBy=d4111948983, createdName=1e10c84am36(暂无匿称), createdTime=Sat Oct 08 08:37:38 CST 2016, time=2016-10-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2003347, encodeId=d657200334ebe, content=<a href='/topic/show?id=5012890397' target=_blank style='color:#2F92EE;'>#HIV患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=100, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8903, encryptionId=5012890397, topicName=HIV患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b505306, createdName=医生2394, createdTime=Wed Jun 14 09:39:00 CST 2017, time=2017-06-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1322359, encodeId=ca4d1322359f4, content=<a href='/topic/show?id=cde152e227a' target=_blank style='color:#2F92EE;'>#性行为#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=91, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=52722, encryptionId=cde152e227a, topicName=性行为)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1e1c493, createdName=xugc, createdTime=Fri Jul 15 11:39:00 CST 2016, time=2016-07-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1356088, encodeId=1c501356088ea, content=<a href='/topic/show?id=b0702e84b9' target=_blank style='color:#2F92EE;'>#ART#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=103, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2784, encryptionId=b0702e84b9, topicName=ART)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Fri Jul 15 11:39:00 CST 2016, time=2016-07-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1479615, encodeId=3c9914e96158e, content=<a href='/topic/show?id=762b2e9464' target=_blank style='color:#2F92EE;'>#ART治疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=81, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2794, encryptionId=762b2e9464, topicName=ART治疗)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ec107553788, createdName=ms55066533437992, createdTime=Fri Jul 15 11:39:00 CST 2016, time=2016-07-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1615842, encodeId=ac59161584286, content=<a href='/topic/show?id=5882260898d' target=_blank style='color:#2F92EE;'>#伴侣#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=26089, encryptionId=5882260898d, topicName=伴侣)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2b3b19689320, createdName=ms3892185887221420, createdTime=Fri Jul 15 11:39:00 CST 2016, time=2016-07-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=93112, encodeId=a62d9311221, content=要注意防护措施, beContent=null, objectType=article, channel=null, level=null, likeNumber=142, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=90f31612316, createdName=xiaotaiyang1, createdTime=Thu Jul 14 19:19:00 CST 2016, time=2016-07-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=93030, encodeId=179293030e0, content=算是研究的进步,不过存在HIV感染率升高的风险, beContent=null, objectType=article, channel=null, level=null, likeNumber=130, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20170701/IMG595791009FB761316.jpg, createdBy=abd01695121, createdName=吴教授, createdTime=Thu Jul 14 08:12:00 CST 2016, time=2016-07-14, status=1, ipAttribution=)]
    2016-07-14 吴教授

    算是研究的进步,不过存在HIV感染率升高的风险

    0

相关资讯

JHM:抗逆转录病毒治疗HIV感染患者院内的死亡趋势

目的:人类免疫缺陷病毒(HIV)感染的住院患者死亡率不能很好地描述。我们试图描述感染艾滋病毒的患者抗逆转录病毒(ART)时期院内死亡率,确定与死亡率相关的因素。方法:我们回顾了1995年1月1日到2011年12月31日城市教学医院住院的死于感染艾滋病毒患者的医疗记录。我们评估在早期和晚期抗逆转录病毒的使用和由于获得性免疫缺陷综合征(AIDS)和非获得性免疫缺陷综合征(non-AIDS)的死亡,确定

NEJM:初始抗逆转录病毒治疗早期无临床症状的HIV感染

来自无症状人类免疫缺陷病毒(HIV)感染的患者(他们的CD4+计数超过了350个细胞/mm3)的随机试验数据缺乏初始抗逆转录病毒治疗的益处和风险。      研究人员随机分配的HIV阳性且CD4+计数超过500细胞/mm3的成人患者立即(立即治疗组),或推迟治疗(直到CD4+计数下降到350细胞/mm3,或直到获得性免疫缺陷综合症(AIDS)或其他状态的发展),即

Lancet:成人一线抗逆转录病毒治疗的监测和转换

背景:HIV-1病毒载量检测,建议监测抗逆转录病毒疗法(ART),但不是普遍可用。该研究的目的是评估一线ART(在撒哈拉以南的非洲切换到二线ART)的监测。    方法:我们做了一个协作队列研究分析了来自非洲东部,南部和西部的16个国家参加国际流行病学的数据库来评估艾滋病(IeDEA)。该研究包括感染HIV-1并在2004年1月和2013年1月间开始结合ART治疗的成

Lancet:婴儿早期抗逆转录病毒治疗后常规HIV抗体测试

背景:早期抗逆转录病毒疗法(ART)和病毒学抑制会影响进化的抗体对HIV感染的反应。该研究的目的是评估婴儿血清阴性早期ART治疗的频率和预测。    方法:研究人员对治疗艾滋病的早期抗逆转录病毒疗法(CHER)试验中的三个组进行了两两比较,从2005年7月开始,2011年7月完成。在这个试验中,5.7-12.0周感染HIV,并有至少25%的CD4阳性T淋巴细胞的婴儿被

Lancet Infect Dis:对于 HIV-1 应采用早期还是延迟抗逆转录病毒疗法?

背景使用抗逆转录病毒治疗 HIV-1 感染降低了 AIDS-相关发病率和死亡率,并防止了 HIV-1 的性传播。 但是,出于减少 HIV-1感染进展或非-AIDS 临床事件的目的,开始抗逆转录病毒治疗的最佳时间尚属未知。 我们此前曾报告早期抗逆转录病毒治疗可将 HIV-1 传播减少96%。 我们的研究目的是:比较早期与延迟开始抗逆转录病毒治疗对临床预后的影响。方法HPTN 052 试验是一项在九个

Nature:HIV感染者体内病毒储存库的建立极早

病毒储存库的存在是治愈HIV-1感染的一个最主要障碍,HIV病毒可以在细胞中潜伏多年,逃避抗逆转录病毒药物的破坏效应。然而,对于急性HIV感染过程中病毒储存库建立的时间和地点,或是它们对于早期抗逆转录病毒治疗(ART)的敏感程度人们却知之甚少。现在,由贝斯以色列女执事医疗中心(BIDMC)以及美国军方艾滋病研究项目的研究人员领导的一个研究小组,证实在猕猴直肠内感染猴免疫缺陷病毒(SIV)之后,可检

Baidu
map
Baidu
map
Baidu
map